These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28045934)

  • 1. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
    Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
    PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis.
    Vesga JF; Lienhardt C; Nsengiyumva P; Campbell JR; Oxlade O; den Boon S; Falzon D; Schwartzman K; Churchyard G; Arinaminpathy N
    BMC Med; 2022 May; 20(1):182. PubMed ID: 35581650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
    Kendall EA; Azman AS; Cobelens FG; Dowdy DW
    PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for advancing tuberculosis control efforts through novel therapies.
    Salomon JA; Lloyd-Smith JO; Getz WM; Resch S; Sánchez MS; Porco TC; Borgdorff MW
    PLoS Med; 2006 Aug; 3(8):e273. PubMed ID: 16866578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.
    Fofana MO; Knight GM; Gomez GB; White RG; Dowdy DW
    PLoS One; 2014; 9(5):e96389. PubMed ID: 24816692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines.
    Wilkinson T; Garcia-Prats AJ; Sachs T; Paradkar M; Suryavanshi N; Kinikar A; Frias MV; Sinanovic E; Hesseling AC; Seddon JA; Palmer M
    PLoS One; 2024; 19(7):e0305930. PubMed ID: 39042708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.
    Arinaminpathy N; Gomez GB; Sachdeva KS; Rao R; Parmar M; Nair SA; Rade K; Kumta S; Hermann D; Hanson C; Chin DP; Dewan P
    PLoS One; 2020; 15(3):e0230808. PubMed ID: 32218585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis.
    Denkinger CM; Kampmann B; Ahmed S; Dowdy DW
    BMC Infect Dis; 2014 Sep; 14():477. PubMed ID: 25186052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.
    Kendall EA; Schumacher SG; Denkinger CM; Dowdy DW
    PLoS Med; 2017 Dec; 14(12):e1002472. PubMed ID: 29240766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
    Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
    BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.
    Menzies NA; Allwood BW; Dean AS; Dodd PJ; Houben RMGJ; James LP; Knight GM; Meghji J; Nguyen LN; Rachow A; Schumacher SG; Mirzayev F; Cohen T
    Nat Commun; 2023 Oct; 14(1):6182. PubMed ID: 37794037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
    Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
    BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.